>>

>>

抑制剂/激活剂

>>

凋亡与自噬

>>

Temozolomide 替莫唑胺; NSC 362856; CCRG 81045; TMZ

Temozolomide (NSC 362856) 是一种可透过血脑屏障的口服活性的 DNA 烷基化 (DNA alkylating) 剂。Temozolomide 也是一种促自噬 (autophagy) 和促凋亡剂 (apoptosis)。Temozolomide 对以低水平的 O6-烷基鸟嘌呤 DNA 烷基转移酶 (OGAT) 和功能失配修复系统为特征的肿瘤细胞有效。Temozolomide 具有抗肿瘤和抗血管生成作用。

货号：
TK0248
规格：

10mg

50mg

100mg
价格：
￥0.00

产品参数

CAS No.	85622-93-1
生物活性	Temozolomide (NSC 362856) is an oral active DNA alkylating agent that crosses the blood-brain barrier. Temozolomide is also a proautophagic and proapoptotic agent. Temozolomide is effective against tumor cells that are characterized by low levels of O6-alkylguanine DNA alkyltransferase (OGAT) and a functional mismatch repair system. Temozolomide has antitumor and antiangiogenic effects.
分子式	C6H6N6O2
分子量	194.15
运输条件	Room temperature in continental US; may vary elsewhere.
储存条件	-20°C, protect from light, stored under nitrogen
溶解性数据	DMSO : 20.83 mg/mL (107.29 mM; Need ultrasonic) H2O : 2.86 mg/mL (14.73 mM; Need ultrasonic)
体内研究	Temozolomide (TZM), as a single agent, does not significantly increase mdian survival time (MST) with respect to control. Noteworthy, intracranial injection of NU1025, immediately before the administration of 100 or 200 mg/kg Temozolomide, significantly increases lifespans with respect to controls or to groups treated with Temozolomide only. When Temozolomide is fractionated, the increase in lifespan (ILS) obtained with this schedule is higher than that observed when NU1025 is combined with a single injection of Temozolomide (statistical comparison of survival curves: NU1025 intracranially+Temozolomide 100 mg/kg×2 vs NU1025+Temozolomide 200 mg/kg; P=0.023).
体外研究	Temozolomide (TZM) is a methylating agent that crosses the blood-brain barrier and is indicated for malignant gliomas and metastatic melanomas. Temozolomide is effective against tumor cells that are characterized by low levels of O-alkylguanine DNA alkyltransferase (OGAT) and a functional mismatch repair system (MR). Determination of the IC50 for Temozolomide (TZM) in different cell lines gave values ranging from 14.1 to 234.6 μM that fell into two clearly differentiated groups: cell lines with low IC50 values (<50 μM), which include A172 (14.1±1.1 μM) and LN229 cells (14.5±1.1 μM), and those with high IC50 values (>100 μM), which include SF268 (147.2±2.1 μM) and SK-N-SH cells (234.6±2.3 μM).
文献	•Brain. 2021 Mar 3;144(2):615-635. •J Pineal Res. 2016 Sep;61(2):208-17. •Theranostics. 2020 Jul 25;10(21):9477-9494. •Neuro Oncol. 2019 Nov 4;21(11):1423-1435. •ACS Appl Mater Interfaces. 2019 Oct 30;11(43):39525-39533. •Cancer Lett. 2021 Mar 1;500:208-219. •Cell Death Dis. 2021 Oct 16;12(11):952. •JCI Insight. 2021 May 10;6(9):141486. •Free Radic Biol Med. 2021 Jun 26;S0891-5849(21)00393-2. •Brain Behav Immun. 2020 Jul;87:568-578. •Cancer Sci. 2020 Nov;111(11):4142-4153. •Front Cell Dev Biol. 2021 May 11;9:678209. •Front Cell Dev Biol. 2021 Feb 1;9:620883. •Int J Biol Sci. 2021; 17(12): 3013-3023. •Acta Pharmacol Sin. 2020 Jul 31. •Acta Pharmacol Sin. 2021 Jan;42(1):108-114. •Biomedicines. 2020 Sep 10;8(9):339. •Biomedicines. 2020 Jun 4;8(6):151. •Cancer Cell Int. 2021 Sep 26;21(1):514. •Neoplasia. 2021 Jan;23(1):58-67. •Eur J Pharm Biopharm. 2021 Feb 7;S0939-6411(21)00039-4. •iScience. 30 December 2021. •J Cell Mol Med. 2021 Dec 28. •J Cell Mol Med. 2021 Jul 21. •Life Sci. 2021 Jan 15;265:118734. •J Mol Med (Berl). 2019 Aug;97(8):1183-1193. •Drug Des Dev Ther. 2021 Apr 21;15:1641-1652. •Am J Transl Res. 2019 Apr 15;11(4):2470-2476. •Neurochem Int. 2021 Aug 9;150:105155. •Oncol Rep. 2021 Apr;45(4):44. •J Appl Toxicol. 2019 May;39(5):726-734. •Clin Transl Oncol. 2020 Aug;22(8):1252-1262. •PLoS One. 2019 Oct 21;14(10):e0224130. •Cancer Biother Radiopharm. 2020 Mar;35(2):101-108. •Mol Imaging Biol. 2020 Feb;22(1):124-133. •Yonsei Med J. 2021 Sep;62(9):843-849. •Immunopharmacol Immunotoxicol. 2021 Aug 26;1-13. •Exp Ther Med. September 2, 2021. •Anatol J Cardiol. 2019 Nov;22(5):232-239. •Research Square Preprint. 2021 Oct. •Data Brief. 22 September 2021, 107394. •Research Square Preprint. 2021 Aug. •Neuro-Oncology Advances. 2021 May 8. •Research Square Preprint. 2021 Apr. •Cell Physiol Biochem. 2018;48(4):1694-1702. •Cell Physiol Biochem. 2018;45(2):819-831. •Oncotarget. 2016 May 17;7(20):29116-30.
纯度及产品资料	98%

推荐产品